ARPA Bio
in tune with innovative solutions for early therapeutic intervention...
About us
We are a preclinical-stage Biotech startup in Switzerland, dedicated to developing innovative diagnostic and therapeutic tools for the treatment of Alzheimer's disease. Our patented technology targets early, neurotoxic seeds prior to the formation of amyloid-beta oligomers or protofibrils, which is why we clearly distinguish from the currently available clinical therapy for AD. The Arpa Bio team is composed of neuroscientists with over 25 years of research experience in the field of neurodegenerative diseases.
CEO / Co-Founder
To be announced shortly
CSO / Co-Founder
To be announced shortly
CFO
To be announced
Director R&D
To be announced shortly
